Drug Trial Radar · NCT00610363
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
Last checked: Nov 20, 2026Latest source record: May 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Nov 2007
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use in preventing gout attacks in participants who had gout.
Conditions
- Gout
Interventions
RilonaceptBiological
Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
Placebo (for Rilonacept)Other
Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12)Time frame: Day 1 (Baseline) to Day 84 (Week 12)
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Site not named
San Diego, California
Site not named
Santa Maria, California
Site not named
Whittier, California
Site not named
Colorado Srings, Colorado
Site not named
DeLand, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
Dunwoody, Georgia
Site not named
Honolulu, Hawaii
Site not named
Boise, Idaho
Site not named
Indianapolis, Indiana
Site not named
South Bend, Indiana
Site not named
Owensboro, Kentucky
Site not named
Wheaton, Maryland
Site not named
Billings, Montana
Site not named
Omaha, Nebraska
Site not named
Reno, Nevada
Site not named
Albany, New York
Site not named
Plainview, New York
Site not named
Roslyn, New York
Site not named
Monroe, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Mayfield Village, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Duncansville, Pennsylvania
Site not named
West Reading, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Grenville, South Carolina
Site not named
Dallas, Texas
Site not named
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.